- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07711730
Telecare Psychosocial and Cognitive Intervention for Children and Adolescents With Limb-Girdle Muscular Dystrophy (TPCLGMD)
13 de julho de 2026 atualizado por: University of Deusto
Telecare-Mediated Psychosocial and Cognitive Intervention for Children and Adolescents With Limb-Girdle Muscular Dystrophy
This clinical trial aims to evaluate the efficacy of a telecare-mediated psychosocial and cognitive intervention for children and adolescents aged 7 to 17 with limb-girdle muscular dystrophy.
This group-based intervention (comprising 5 participants) consists of 12 weekly one-hour sessions.
The objective of the intervention is to improve the participants' quality of life as well as to reduce their symptomatology by targeting areas such as social cognition, emotional and personal management, cognitive restructuring, relaxation strategies, social skills, and coping strategies.
Visão geral do estudo
Status
Recrutamento
Condições
Intervenção / Tratamento
Descrição detalhada
Development and implementation of a psychosocial and cognitive tele-assistance programme for groups of children and adolescents affected by limb-girdle muscular dystrophy.
In this project the variables of interest and intervention include social cognition, quality of life, psychological symptomatology and coping strategies.
The aim of this study is to test whether this programme improves the indicators in the mentioned variables.
Tipo de estudo
Intervencional
Inscrição (Estimado)
30
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Biscay
-
Bilbao, Biscay, Espanha, 48007
- Recrutamento
- University of Deusto
-
Contato:
- Óscar Universidad de la Iglesia de Deusto
- Número de telefone: -34 944139377
- E-mail: oscar.martinez@deusto.es
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
Aceita Voluntários Saudáveis
Não
Descrição
Inclusion Criteria:
- To be diagnosed with limb-girdle muscular dystrophy
- Being between 7 and 17 years old
- Having signed an informed consent form through their legal guardians prior to participation in the study
- Having Spanish as one of their main languages
- Having access to a computer (with a camera, microphone and speakers integrated) and Internet connection to take part in the videoconferences
Exclusion Criteria:
- Presence of any other diagnosis or sensory deficit that would prevent the application of the tests or hinder the correct performance of the intervention's activities
- Being illiterate
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Ao controle
Grupo de controle da lista de espera
|
The intervention is carried out in groups of 5 participants and is organised in 12 sessions: 1 session per week of 1h duration.
The objective of the intervention is to improve the participants' quality of life as well as to reduce their symptomatology by targeting areas such as social cognition, emotional and personal management, cognitive restructuring, relaxation strategies, social skills, and coping strategies.
|
|
Experimental: Intervention
Neuro-psychosocial intervention with 12 groupal sessions is offered
|
The intervention is carried out in groups of 5 participants and is organised in 12 sessions: 1 session per week of 1h duration.
The objective of the intervention is to improve the participants' quality of life as well as to reduce their symptomatology by targeting areas such as social cognition, emotional and personal management, cognitive restructuring, relaxation strategies, social skills, and coping strategies.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Cognição social - Teoria da mente - NEPSY-II
Prazo: 3 meses após a intervenção
|
O subteste Teoria da Mente do Domínio de Percepção Social do NEPSY-II na edição espanhola (Korkman et al., 2014) avalia a linguagem figurativa, as habilidades de imitação e a capacidade de compreender os pensamentos, ideias e crenças dos outros e também avalia a capacidade de uma pessoa compreender como as emoções se relacionam com o contexto social.
|
3 meses após a intervenção
|
|
Social cognition - Emotion Recognition
Prazo: 3 months after the intervention
|
Affect Recognition subtest of the Social Perception Domain of the NEPSY-II in the Spanish edition (Korkman et al., 2014) measures the capacity to identify emotions (happy, sad, neutral, afraid, irrationally angry, and disgust) in various images of children.
|
3 months after the intervention
|
|
Social cognition - Theory of mind - Happé's Strange Stories
Prazo: 3 months after the intervention
|
The Happé's Strange Stories Test is a well-known test of ToM (Happé, 1994; Spanish version: Pousa, 2002).
In this study, we used the White et al. (2009) version that has eight story-types.
This test evaluates participants' capacity to comprehend nonliteral meanings through the reading of brief vignettes.
|
3 months after the intervention
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Health-related quality of life
Prazo: 3 months after the intervention
|
How an individual's health status impacts their overall well-being and ability to lead a satisfying life The perception of HRQoL is assessed in both healthy and chronically ill children using the Spanish version of the Pediatric Quality of Life Inventory (PedsQLTM 4.0) (Varni et al., 2001).
We used the self-report questionnaire in this study for three age ranges: 5-7, 8-12, and 13-18.
Physical functioning, emotional functioning, social functioning, and academic functioning are the four dimensions covered by the 23-item assessment.
The PedsQL 4.0 provides a physical and a psychosocial summary score in addition to a total score.
It is answered through a likert scale with 5 response options that are then converted into quantitative scores ranging from 0-100 points, with a higher score being a better HRQoL.
|
3 months after the intervention
|
|
Health-related quality of life neuromuscular
Prazo: 3 months after the intervention
|
How an individual's health status impacts their physical well-being and ability to communicate their disease The perception of HRQoL is assessed in both healthy and chronically ill children using the Spanish version of the Pediatric Quality of Life Inventory Neuromuscular (PedsQLTM Neuromuscular) (Varni et al., 2001).
We used the self-report questionnaire in this study for three age ranges: 5-7, 8-12, and 13-18.
Neuromuscular disease, communication and family functioning are the three dimensions covered by the 25-item assessment.
The PedsQL Neuromuscular provides a physical and a communication skills summary score in addition to a total score.
It is answered through a likert scale with 5 response options that are then converted into quantitative scores ranging from 0-100 points, with a higher score being a better HRQoL.
|
3 months after the intervention
|
|
Children's Depression Inventory-Short
Prazo: 3 months after the intervention
|
Depression symptoms The Children's Depression Inventory-Short (Kovacs, 1992; Spanish version: Barrio et al. 2012) measures key signs of depression such as sadness, sleep issues, and low self-esteem in just a few.
It is a 10-item self-report questionnaire designed to quickly screen for depressive symptoms in youths aged 7 to 17.
Each choice is scored from 0 to 2, with higher scores reflecting greater symptom severity.
|
3 months after the intervention
|
|
Child Medical Fear
Prazo: 3 months after the intervention
|
To what children have fear in a medical context The Child Medical Fear scale (Broome et al., 1988; Spanish version: San Martin-Rodriguez et al., 2021) is an assessment tool used to measure a child's anxiety and fear regarding medical events and healthcare environments.
It has 17 items in total, and the scores are rated on a 3-point Likert scale: Not at all (0 points), A little (1 point), and A lot (2 points).
It helps pediatricians and psychologists identify specific triggers-such as physical pain or loss of control-so they can tailor medical care to reduce a child's stress.
|
3 months after the intervention
|
|
Psychopathology
Prazo: 3 months after the intervention
|
Behavioral and emotional symptoms The Child Behavior Checklist for Ages 6-18 (CBCL/6-18) (Achenbach & Rescorla, 2001) is a multiaxial assessment tool for identifying behavioral and emotional issues in children and adolescents that is aligned with the ASEBA (Achenbach System of Empirically Based Assessment).
It has 113 items total, broken down into eight scales for the following syndromes: anxious/depressed, withdrawn/depressed, somatic complaints, social problems, thinking problems, attention problems, rule-breaking behavior and aggressive behavior.
Scores for internalizing, externalizing, and overall difficulties are also provided by the items.
|
3 months after the intervention
|
|
Strengths and Difficulties Questionnaire
Prazo: 3 months after the intervention
|
Mental, emotion and behaviour health possible problems The Strengths and Difficulties Questionnaire (Goodman, 1997; Spanish version: García et al., 2000) is a brief behavioral and emotional screening tool for children and adolescents aged 2 to 17.
It uses 25 questions across five categories (emotional symptoms, conduct problems, hyperactivity, peer relationship problems and prosocial behavior) to assess both psychological problems and positive social behaviors.
|
3 months after the intervention
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
1 de março de 2026
Conclusão Primária (Estimado)
30 de dezembro de 2026
Conclusão do estudo (Estimado)
1 de junho de 2027
Datas de inscrição no estudo
Enviado pela primeira vez
13 de julho de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
13 de julho de 2026
Primeira postagem (Real)
17 de julho de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
17 de julho de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
13 de julho de 2026
Última verificação
1 de julho de 2026
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças musculoesqueléticas
- Doenças do Sistema Nervoso
- Doenças Musculares
- Doenças Neuromusculares
- Doenças Genéticas, Congênitas
- Distúrbios Musculares Atróficos
- Distrofias Musculares
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Comportamento
- Comportamento social
- Distrofias Musculares, Membros-Cintura
- Habilidades sociais
Outros números de identificação do estudo
- PI2026090
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
SIM
Descrição do plano IPD
This plan is open to other reserchers to contact the principal investigator of the study.
Prazo de Compartilhamento de IPD
The data is available from now until 2029.
Critérios de acesso de compartilhamento IPD
This plan is open to other reserchers to contact the principal investigator of the study.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .